HD201
Trastuzumab Biosimilar
Breast Cancer, Gastric Cancer
Discovery
Preclinical
Phase I
Phase III
Filing
Approval
HD204
Bevacizumab Biosimilar
Solid Tumors
Discovery
Preclinical
Phase I
Phase III
Filing
Approval
PBP1502
Adalimumab Biosimilar
Arthritis
Discovery
Preclinical
Phase I
Phase III
Filing
Approval
PBP1601
Denosumab Biosimilar
Bone Loss, Osteoporosis
Discovery
Preclinical
Phase I
Phase III
Filing
Approval
PBP1602
Aflibercept Biosimilar
Macular Edema, Metastatic Colorectal Cancer, Retinopathy
Discovery
Preclinical
Phase I
Phase III
Filing
Approval
PBP1603
Eculizumab Biosimilar
Atypical Hemolytic Uremic Syndrome, Paroxysmal Nocturnal Hemoglobinuria
Discovery
Preclinical
Phase I
Phase III
Filing
Approval
PBP1701
Ipilimumab Biosimilar
Metastatic / Unresectable Melanoma
Discovery
Preclinical
Phase I
Phase III
Filing
Approval
PBP1801
Pertuzumab Biosimilar
Breast Cancer
Discovery
Preclinical
Phase I
Phase III
Filing
Approval
PBP2001
Ramucirumab Biosimilar
Metastatic / Gastric Junction Adenocarcinoma
Discovery
Preclinical
Phase I
Phase III
Filing
Approval
PBP2002
Natalizumab Biosimilar
Active Crohn’s Disease
Discovery
Preclinical
Phase I
Phase III
Filing
Approval
PBP2101
Nivolumab Biosimilar
Metastatic Urothelial Carcinoma
Discovery
Preclinical
Phase I
Phase III
Filing
Approval
PBP2102
Pembrolizumab Biosimilar
Metastatic / Unresectable Melanoma
Discovery
Preclinical
Phase I
Phase III
Filing
Approval